Cwm LLC increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 137.9% during the second quarter, Holdings Channel reports. The fund owned 83,970 shares of the biopharmaceutical company’s stock after buying an additional 48,672 shares during the period. Cwm LLC’s holdings in Gilead Sciences were worth $5,943,000 at the end of the most recent reporting period.
Several other institutional investors also recently added to or reduced their stakes in GILD. Hall Laurie J Trustee raised its position in Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 250 shares during the last quarter. Cable Hill Partners LLC raised its position in Gilead Sciences by 51.9% in the first quarter. Cable Hill Partners LLC now owns 1,584 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 541 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. raised its position in Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 1,400 shares during the last quarter. Dubuque Bank & Trust Co. raised its position in Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 267 shares during the last quarter. Finally, Penserra Capital Management LLC raised its position in Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 144 shares during the last quarter. Institutional investors and hedge funds own 74.03% of the company’s stock.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at 73.76 on Friday. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $88.85. The firm has a 50-day moving average price of $68.32 and a 200-day moving average price of $68.63. The stock has a market cap of $96.38 billion, a price-to-earnings ratio of 7.80 and a beta of 1.21.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.18 by $0.02. The company had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.66 billion. Gilead Sciences had a net margin of 43.42% and a return on equity of 76.64%. Equities analysts expect that Gilead Sciences, Inc. will post $8.41 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Thursday, June 29th. Shareholders of record on Friday, June 16th were issued a $0.52 dividend. The ex-dividend date was Wednesday, June 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.82%. Gilead Sciences’s dividend payout ratio (DPR) is presently 21.99%.
COPYRIGHT VIOLATION WARNING: This piece was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://stocknewstimes.com/2017/07/23/cwm-llc-buys-48672-shares-of-gilead-sciences-inc-nasdaqgild.html.
A number of equities analysts have weighed in on GILD shares. Jefferies Group LLC reiterated a “buy” rating and set a $82.00 price objective on shares of Gilead Sciences in a research note on Thursday, April 6th. Cowen and Company restated a “buy” rating and issued a $100.00 price target on shares of Gilead Sciences in a research note on Monday, April 17th. Vetr lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $73.87 price target for the company. in a research note on Tuesday, April 11th. Stifel Nicolaus restated a “buy” rating and issued a $87.00 price target on shares of Gilead Sciences in a research note on Monday, April 24th. Finally, Piper Jaffray Companies restated a “buy” rating on shares of Gilead Sciences in a research note on Friday, April 21st. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $80.09.
In other Gilead Sciences news, Director John Francis Cogan sold 9,943 shares of Gilead Sciences stock in a transaction on Tuesday, May 9th. The shares were sold at an average price of $67.25, for a total value of $668,666.75. Following the transaction, the director now owns 47,562 shares in the company, valued at approximately $3,198,544.50. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the completion of the transaction, the insider now owns 3,199,969 shares in the company, valued at approximately $227,197,799. The disclosure for this sale can be found here. In the last quarter, insiders sold 88,276 shares of company stock worth $6,230,610. 1.30% of the stock is owned by company insiders.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
